Also, in non-oncogene-driven NSCLC, ICIs targeting PD-1 or PD-L1 have emerged as the cornerstone of first-line therapy or in combination with platinum-doublet chemotherapy (PT), regardless of histology or PD-L1 expression [269]. Here, PDCD1 is linked to non-small cell lung carcinoma.